ATE202926T1 - Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung - Google Patents

Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung

Info

Publication number
ATE202926T1
ATE202926T1 AT95915300T AT95915300T ATE202926T1 AT E202926 T1 ATE202926 T1 AT E202926T1 AT 95915300 T AT95915300 T AT 95915300T AT 95915300 T AT95915300 T AT 95915300T AT E202926 T1 ATE202926 T1 AT E202926T1
Authority
AT
Austria
Prior art keywords
drug
formulation
active ingredients
controlled release
microcapsules
Prior art date
Application number
AT95915300T
Other languages
English (en)
Inventor
Virginia Freeman
Zebunnissa Ramtoola
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Application granted granted Critical
Publication of ATE202926T1 publication Critical patent/ATE202926T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95915300T 1994-04-06 1995-04-06 Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung ATE202926T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE940292A IE940292A1 (en) 1994-04-06 1994-04-06 Biodegradable microcapsules and method for their manufacture
PCT/IE1995/000025 WO1995027482A1 (en) 1994-04-06 1995-04-06 Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules

Publications (1)

Publication Number Publication Date
ATE202926T1 true ATE202926T1 (de) 2001-07-15

Family

ID=11040358

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95915300T ATE202926T1 (de) 1994-04-06 1995-04-06 Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung

Country Status (11)

Country Link
EP (1) EP0754034B1 (de)
JP (1) JPH09511517A (de)
AT (1) ATE202926T1 (de)
AU (1) AU2223095A (de)
DE (1) DE69521688T2 (de)
DK (1) DK0754034T3 (de)
ES (1) ES2158101T3 (de)
GR (1) GR3036798T3 (de)
IE (1) IE940292A1 (de)
PT (1) PT754034E (de)
WO (1) WO1995027482A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
EP1609477B1 (de) * 1994-12-12 2011-11-09 Omeros Corporation Bespüllungslösung und deren Verwendung zur perioperativen Hemmung von Schmerzen, Entzündungen und/oder Spasmen an einer Gefässstruktur
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
AUPN603895A0 (en) * 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
KR100289471B1 (ko) * 1998-01-19 2001-09-17 김충섭 휀타닐계마취제의이식형서방성제제
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
DE10038364A1 (de) * 2000-08-05 2002-05-02 Hexal Ag Pharmazeutische, Ramipril enthaltende Brauseformulierung
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
AU2004311879B2 (en) 2003-12-31 2010-08-05 Cima Labs Inc. Effervescent oral opiate dosage form
DE102004040458B4 (de) * 2004-08-20 2009-01-29 Meinert, H., Prof. Dr. Glaskörpertamponadepräparat und seine Verwendung
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
DK2197429T3 (en) * 2007-09-03 2016-05-30 Nanotherapeutics Inc Particulate compositions for delivery of poorly soluble drugs
TR201100152A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Amlodipin içeren efervesan bileşimler.
US9566241B2 (en) 2012-02-21 2017-02-14 Auburn University Buprenorphine nanoparticle composition and methods thereof
US20170209374A1 (en) * 2015-09-11 2017-07-27 Pfizer Inc. Methods of controlling the morphology of polymeric nanoparticles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7112083A (de) * 1970-09-16 1972-03-20
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles

Also Published As

Publication number Publication date
DE69521688T2 (de) 2002-05-02
PT754034E (pt) 2001-12-28
IE940292A1 (en) 1995-10-18
EP0754034A1 (de) 1997-01-22
DE69521688D1 (de) 2001-08-16
EP0754034B1 (de) 2001-07-11
ES2158101T3 (es) 2001-09-01
AU2223095A (en) 1995-10-30
WO1995027482A1 (en) 1995-10-19
DK0754034T3 (da) 2001-09-24
GR3036798T3 (en) 2002-01-31
JPH09511517A (ja) 1997-11-18

Similar Documents

Publication Publication Date Title
ATE202926T1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
Bruschi et al. Oral bioadhesive drug delivery systems
FI945621A0 (fi) Säädetysti vapauttava valmiste
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
AR004391A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles.
DE69532678D1 (de) Arzneizubereitungen enthaltend nicht-steroidale entzündungshemmende Arzneimittel
IL119627A0 (en) Controlled-release pharmaceutical preparations
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
US4910205A (en) Transdermal delivery of loratadine
NZ508526A (en) Opioid formulations for treating pain
DE69519685D1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
YU2494A (sh) Farmaceutska formulacija za tretiranje zavisnosti od nikotina
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
DE69922017D1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
CA2168882A1 (en) Therapeutic system for treating psoriasis
CA2187153A1 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
ATE212840T1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
JP2002520269A5 (de)
GEP20063804B (en) Once-a-day oxycodone formulations
RU98109932A (ru) Применение 1-(2-нафт-2-илэтил)-4-(3-трифторметилфенил)-1,2,3,6-тетрагидропиридина для получения лекарственных средств, предназначенных для лечения бокового амиотрафического склероза
AR018465A1 (es) COMPOSICIoN FARMACÉUTICA SoLIDA ORAL, USO DE LA COMPOSICIoN PARA LA FABRICACIoN DE UN MEDICAMENTO PARA LA PREVENCIoN, LA MODULACIoN O EL TRATAMIENTO DE DOLOR O INCOMODIDAD VISCERAL, PARA LA MODULACIoN DE LA SENSIBILIDAD O PERCEPCIoN VISCERAL, PARA MEJORAR LA PERCEPCIoN SENSORIAL DE LA DISTENCIoN REC
HUT55221A (en) Process for producing pharmaceutical composition suitable for transdermal administration

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee